The cancer drugs fund: Where is the evidence for the existence of the cancer drugs fund?

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Chamberlain, Charlotte ^a   Hollingworth, William ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Department of Health Economics ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG COST; DRUG INDUSTRY; HEALTH CARE FINANCING; HUMAN; INFORMATION PROCESSING; LETTER; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PRESCRIPTION; QUALITY OF LIFE; REIMBURSEMENT; SURVIVAL TIME; NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 84907495511     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g5901     Document Type: Letter

References (4)

1. Jack A. Peter Clark: public attitudes support a more favourable assessment for cancer treatments. BMJ 2014;349:g5545. (11 September.)
2. Chamberlain C, Collin SM, Stephens P, Donovan J, Bahl A, Hollingworth W. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales. Br J Cancer 2014 Feb 25[Epub ahead of print] doi:10. 1038/bjc.2014.86.
3. Stephens P, Thomson D. The Cancer Drug Fund 1 year on-success or failure? Lancet Oncol 2012;13:754-7.
4. Foot C, Harrison T. How to improve cancer survival: explaining England's relatively poor rates. King's Fund and Cancer Research UK, 2011.